GleamWall
中文EN

BFRG BullFrog AI Holdings, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1829247 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY4.1%
TTM EPS YoY40.6%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-184.0%
ROA-152.0%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets12.4%
Debt / equity0.00x
Current ratio7.75x
Interest coverage-1,202.80x

Cash quality & payout

Operating cash flow / net income0.97x
Accruals ratio-4.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$63,578$215,385—$0$83,413$33,257——
Cost of revenue$53,542$108,486—$0$68,043$26,735——
Gross profit$10,036$106,899—$0$15,370$6,522——
R&D expense$439,240$339,456$434,819$397,189$345,992$480,297$576,260$590,856
SG&A expense$1.62M$1.19M$1.18M$1.10M$1.24M$995,898$1.48M$1.18M
Operating income-$2.05M-$1.42M-$1.61M-$1.50M-$1.57M-$1.47M-$2.06M-$1.77M
Interest expense$1,497$2,373$982$622$1,543$2,449$1,015$2,008
Net income-$2.01M-$1.37M-$1.59M-$1.48M-$1.55M-$1.45M-$2.02M-$1.71M
EBITDA-$2.05M-$1.42M-$1.61M-$1.50M-$1.57M-$1.47M-$2.06M-$1.77M
EPS (basic)-0.11-0.07-0.12—-0.15-0.15-0.21—
EPS (diluted)-0.11-0.07-0.12—-0.15-0.15-0.21—
Weighted avg. shares (diluted)18.87M18.81M12.95M—10.38M9.71M9.69M—
Balance sheet
Cash & equivalents$4.99M$6.92M$5.08M$2.18M$2.10M$2.58M$3.80M$5.44M
Receivables$175,000——$0$58,335———
Current assets$5.57M$7.47M$5.32M$2.58M$2.54M$2.70M$4.08M$5.55M
PP&E, net$1,231$1,662$2,094$2,525$2,956$3,387$3,818$4,250
Total assets$5.79M$7.69M$5.54M$2.81M$2.70M$2.87M$4.09M$5.55M
Current liabilities$719,310$706,590$652,072$672,022$758,701$681,084$839,397$588,090
Short-term debt————$55,606$110,291$164,070—
Total liabilities$719,310$706,590$652,072$672,022$758,701$681,084$839,397$588,090
Shareholders' equity$5.08M$6.99M$4.89M$2.14M$1.94M$2.19M$3.25M$4.96M
Shares outstanding18.69M18.54M18.45M11.42M10.42M9.63M9.42M9.11M
Cash flow statement
Operating cash flow-$1.88M-$1.51M-$1.69M-$1.18M-$1.11M-$1.43M-$1.80M-$1.27M
Investing cash flow$0———$0———
Financing cash flow-$44,622$3.35M$4.59M$1.38M$624,249$208,680$164,070$2.47M
Depreciation & amortization$431$432$431$431$431$432$431$431
Stock-based compensation$396$1,188$126,656$154,208$145,388$177,905$300,288$214,279

Free plan shows the latest 8 periods; Pro shows all 19 🔒

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.